News
Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
The breakup between Hims & Hers and Novo Nordisk has hit HIMS stock hard with a 35% crash. Click here for a full investment ...
The Investment Committee discuss their strategy on some stocks on the move today. California Democrats stage internal war ...
Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press ...
Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback